





Name : Ms. Nitika Bohra Registration on: 16-Mar-2022 10:47

Lab ID : 032221201956 Ref. ld: Collected on

Sex/Age : Female / 29 Years Approved on : 16-Mar-2022 11:53

Ref. By Sample Type : EDTA Blood

: Bob Health Checkup@Godhra Patient Source Location

COMPLETE BOOD COUNT

Test HB and Indices	Result	Unit	Biological Ref. Interval
Hemoglobin	L 11.0	g/dL	12.0 - 16.0
RBC Count	3.86	million/cmm	3.8 - 4.8
Hematocrit	L 32.6	%	36 - 48
MCV	84.5	fL	83 - 101
MCH	28.5	pg	26.4 - 33.2
MCHC	33.7	g/dL	31.8 - 35.9
RDW CV	H 14.50	%	11.6 - 14
Total WBC and Differen	tial Count		
WBC Count	8210	/cmm	4000 - 10000
Differential Count			Absolute Count
Neutrophils	76.6	% 40 - 80	6289 /cmm 2000 - 6700
Lymphocytes	16.7	% 20 - 40	1371 /cmm 1000 - 3000
Eosinophils	0.0	% 1 - 6	0 /cmm 20 - 500
Monocytes	6.5	% 2 - 10	534 /cmm 200 - 1000
Basophils	0.2	% 0 - 2	16 /cmm 0 - 100
Platelet Count			

Platelet Count

ESR

Erythrocytes Sedimentation Rate

Dr. Harsh shah Dr. Farzana Vali M.D., D.N.B. M.B., D.C.P. # Referred Test This is an Electronically Authenticated Report.

204000

H 63

/cmm

mm/1hr

Dr Nayan Modi

M.D.

150000 - 410000

0 - 21

Page 1 of 7

06-Apr-2022 18:18 Printed on: Report Status: Final







Name : **Ms. Nitika Bohra** Registration on : 16-Mar-2022 10:47

Lab ID : 032221201956 Ref. ld : Collected on :

Sex/Age : Female / 29 Years Approved on : 16-Mar-2022 11:53

Ref. By : Sample Type : EDTA Blood, Serum

Location : Bob Health Checkup@Godhra Patient Source :

Blood Group

Test Result Unit Biological Ref. Interval

ABO Type "AB"

Rh (D) Type Positive

岁

Dr. Harsh shah M.D., D.N.B.

Referred Test

Dr. Farzana Vali M.B., D.C.P.

This is an Electronically Authenticated Report.

Dr Nayan Modi

M.D.

Page 2 of 7

Report Status: Final Printed on: 06-Apr-2022 18:18









Name : Ms. Nitika Bohra Registration on : 16-Mar-2022 10:47 Lab ID : 032221201956 Ref. ld: Collected on : 16-Mar-2022 13:41 Sex/Age : Female / 29 Years Approved on : 16-Mar-2022 11:52 Ref. By Sample Type : Serum,Fluoride PP

: Bob Health Checkup@Godhra Patient Source Location

Test	Result	Unit	Biological Ref. Interval				
Fasting Blood Sugar	95.1		70 - 110				
Fasting Urine Sugar	Absent		Absent				
Post Prandial Blood Sugar	119.9	mg/dL	70 - 140				
Postprandial Urine Sugar	Not Given		Absent				
Creatinine, Serum Modified Jaffes method	0.71	mg/dL	0.4 - 1.4				
Urea Urease Glutamate Dehydrogenase, UV method	26.4	mg/dL	13 - 40				
Uric Acid Uricase-Peroxidase method	L 1.90	mg/dL	2.6 - 6.0				
SGPT IFCC method without pyridoxal phosphate activation	17.6	U/L	0 - 45				
SGOT IFCC method without pyridoxal phosphate activation	19.0	U/L	5 - 40				
GGT L-?-glutamyl-glycylglycine	7.4	U/L	5 - 50				
	Bilirubin						
Total Bilirubin Diazo reaction	0.28	mg/dL	0.2 - 1.3				
Direct Bilirubin Diazo reaction	0.10	mg/dL	0.0 - 0.4				
Indirect Bilirubin Calculated	0.18	mg/dL	0.1 - 1.1				
Protein							
Total Protein Biuret method	7.01	g/dL	6.0 - 8.5				
Albumin BCG	3.96	g/dL	3.5 - 5.2				
Globulin	H 3.05	g/dL	2.2 - 3.0				
A/G Ratio Calculated	1.30		1.3 - 1.7				

Dr Nayan Modi Dr. Harsh shah M.D. M.D., D.N.B. # Referred Test This is an Electronically Authenticated Report.

Dr. Farzana Vali

M.B., D.C.P.

Page 3 of 7

06-Apr-2022 18:18 Printed on: Report Status: Final







 Name
 : Ms. Nitika Bohra
 Registration on
 : 16-Mar-2022 10:47

 Lab ID
 : 032221201956 Ref. ld :
 Collected on
 : 16-Mar-2022 13:41

 Sex/Age
 : Female / 29 Years
 Approved on
 : 16-Mar-2022 11:52

Ref. By : Sample Type : Serum

Location : Bob Health Checkup@Godhra Patient Source :

Lipid Profile

		1110	
Test	Result	Unit	Biological Ref. Interval
Cholesterol Cholesterol oxidase, Esterase, Peroxidase	H 240.0	mg/dL	Desirable : <200 Borderline High : 200-239 High : >240
Triglyceride GPO-POD	H 150.6	mg/dL	Normal : < 150 Borderline : 150-199 High : 200-499 Very High : > 500
HDL Cholesterol	H 63.7	mg/dL	Low : <40.0 High : >60.0
Direct LDL Direct measured	147.90	mg/dL	Optimal : < 100 Near / above optimal : 100-129 Borderline High : 130-159 High : 160-189 Very High : >190
VLDL Calculated	30.12	mg/dL	15 - 35
CHOL/HDL Ratio	3.8		Up to 5.0
LDL/HDL Ratio	2.3		Up to 3.5

Dr Nayan Modi

Dr. Harsh shah
M.D., D.N.B.

M.B., D.C.P.

Dr. Farzana Vali

Referred Test

This is an Electronically Authenticated Report.

Page 4 of 7

Report Status: Final Printed on: 06-Apr-2022 18:18



Bob Health Checkup@Godhra



Patient Source



LABORATORY REPORT



 Name
 : Ms. Nitika Bohra
 Registration on
 : 16-Mar-2022 10:47

 Lab ID
 : 032221201956 Ref. Id :
 Collected on
 : 16-Mar-2022 13:41

 Sex/Age
 : Female / 29 Years
 Approved on
 : 16-Mar-2022 12:01

 Ref. By
 : EDTA Sample

HbA1c (Glycosylated Hemoglobin)

	` ,	•	
Test	Result	Unit	Biological Ref. Interval
HbA1c	5.38	%	For Screening: Diabetes: >6.5% Pre-Diabetes: 5.7% - 6.4% Non-Diabetes: < 5.7% For Diabetic Patient: Poor Control: > 7.0 %
			Good Control : 6.0-7.0 %
Mean Blood Glucose	107.71	mg/dL	

Explanation:-

Location

- Total haemoglobin A1 c is continuously synthesized in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.
- The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose concentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels.
- The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days, HbA1c has been accepted as a measurement which reflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.
- It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

Erroneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c (HbF) or differences in their glycation from that of HbA (HbS).

Reference: ADA Guideline 2020

岁

Dr. Harsh shah M.D., D.N.B.

Report Status: Final

Dr. Farzana Vali M.B., D.C.P.

M.D.

Referred Test This is an Electronically Authenticated Report.

Page 5 of 7

Printed on: 06-Apr-2022 18:18

Dr Nayan Modi

Laboratory: Opp. Vishwakarma Mandir, L.I.C. Road, Godhara. Ph.: (L) (02672) 243740, 249200 | № 9104937017









 Name
 : Ms. Nitika Bohra
 Registration on : 16-Mar-2022 10:47

 Lab ID
 : 032221201956 Ref. ld : Collected on : 16-Mar-2022 13:41

 Sex/Age
 : Female / 29 Years
 Approved on : 16-Mar-2022 11:50

Ref. By : Sample Type : Serum

Location : Bob Health Checkup@Godhra Patient Source :

Thyroid Function Test

Thyroid I dilotion 100t				
Test	Result	Unit	Biological Ref. Interval	
T3 - Triiodothyronine	1.54	ng/mL	0.58 - 1.59	
T4 - Thyroxine	12.74	micro g/dL	5.13 - 14.06	
TSH - Thyroid Stimulating Hormone	1.1700	microIU/mL	0.35 - 4.94	

тѕн	T3/FT3	T4/FT4	Suggested Interpretation for the Thyroid Function Tests Pattern		
Within Range	Decreased	Within Range	 Isolated Low T3-offen seen in elderly & associated Non-Thyroidal illness. In elderly the drop in T3 level can be upto 25% 		
Raised	Within Range	Within Range	 Isolated High TSH especially in the range of 4.7 to 15 mIU/mI is commonly associated with physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism Intermitted T4 therapy for hypothyroidism Recovery phase after Non-Thyroidal illness 		
Raised	Decreased	Decreased	Chronic autoimmune Thyroiditis Post thyroidectomy, Post radioiodine Hypothyroid phase of transient thyroiditis		
Raised or Within Range	Raised	Raised or Within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies) intermittent T4 therapy or T4 overdose Drug interference-Amiodarone, Heparin, Beta blockers, steroids, anti-epileptics		
Decreased	Raised or within Range	Raised or within Range	Isolated Low TSH - especially in the range of 0.1 to 0.4 offen seen in elderly & associal Non-Thyroidal illness Subclinical Hyperthyroidism Thyroxine ingestion		
Decreased	Decreased	Decreased	Central Hypothyroidism Non-Thyroidal illness Recent treatment for Hyperthyroidism (TSH remains suppressed)		
Decreased	Raised	Raised	 Primary Hyperthyroidism (Graves disease), Multinodular goitre Toxic nodule Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain'a) Gestational thyrotoxicosis with hyperemesis gravidarum 		
Decreased or within range	Raised	Within Range	- T3 toxicosis - Non-Thyroidal illness		

Dr Nayan Modi

M.D.

Dr. Harsh shah M.D., D.N.B.

M.B., D.C.P. Page 6 of 7

Dr. Farzana Vali

Referred Test

This is an Electronically Authenticated Report.

. ..9. . . .

Report Status: Final Printed on: 06-Apr-2022 18:18

Laboratory: Opp. Vishwakarma Mandir, L.I.C. Road, Godhara. Ph.: (L) (02672) 243740, 249200 | № 9104937017







Name : Ms. Nitika Bohra Registration on: 16-Mar-2022 10:47 Lab ID : 032221201956 Ref. ld: Collected on : 16-Mar-2022 13:41 Sex/Age : Female / 29 Years Approved on : 16-Mar-2022 11:53

Ref. By Sample Type : Urine

: Bob Health Checkup@Godhra Patient Source Location

Urine Routine Examination

Test	Result	Unit	Biological Ref. Interval		
Physical Examination					
Volume	10	ml			
Colour	Yellow				
Odour	Ammonical				
Transparency	Slight turbid				
Chemical Examination (Dip Stick Method)					
Reaction	Acidic				
Specific Gravity	1.025		1.005 - 1.030		
Albumin	Absent		Absent		
Urine Glucose	Absent		Absent		
Bile Salts	Absent		Absent		
Bile Pigments	Absent		Absent		
Urine Ketone	Absent		Absent		
Nitrite	Negative		Negative		
Microscopic Examination					
Pus Cells	10-12	/hpf	0 - 5		
Red Cells	Absent	/hpf	0 - 2		
Epithelial Cells	Occassional	/hpf			
Casts	Absent	/hpf			
Crystals	Absent	/hpf			
Amorphous Material	Absent				
Bacteria	Absent		Absent		
Budding Yeast	Absent		Absent		
Trichomonas	Absent				

Dr. Harsh shah Dr. Farzana Vali Dr Nayan Modi

M.D., D.N.B. M.B., D.C.P. M.D. # Referred Test

Page 7 of 7 This is an Electronically Authenticated Report.

06-Apr-2022 18:18 Printed on: Report Status: Final

----- End Of Report -----